The latest have been prostate-specific membrane antigen (PSMA) PET agents for prostate cancer, with 68 Ga-PSMA 11 granted approval to UCLA and UCSF on December 1, 2020 [1] and 18F-DCFPyL (Pylarify) approved in late May 2021 [2]. This evidence concerns the gene FOLH1 and prostate carcinoma.